Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$19.29M+961.40%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Heather Getz
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 218
- Beta
- 1.36
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -9.24
Financials
Revenue
$19.29M+961.4%Net Income
$-11.26MEBITDA
$-9.03MFree Cash Flow
$-9.44MEPS (diluted)
$-0.20Shares Outstanding (diluted)
57.41M+19388.1%Operating Expenses
$23.23MCash & Debt
$30.42MReturn of Capital
$94.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $80.28M | $-38.83M | $-0.83 |
| 2024 | $69.30M | $-37.84M | $-1.33 |
| 2023 | $58.45M | $-46.66M | $-2.04 |
| 2022 | $41.42M | $-44.30M | $-2.73 |
| 2021 | $29.46M | $-33.28M | $-2.30 |
| 2020 | $18.21M | $-28.79M | $-2.23 |
| 2019 | $15.45M | $-22.43M | $-2.26 |
| 2018 | $8.27M | $-21.09M | $-3.25 |
| 2017 | $4.25M | $-21.33M | $-3.29 |
Valuation
TELAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-50.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·1d ago·Negative
TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement MALVERN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Company's Liora Monofilament Scaffold (“Liora”) product.
View source ↗ - Newsglobenewswire.com·36d ago·Negative
TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program
View source ↗ - Newsseekingalpha.com·56d ago·Positive
TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.19 per share
Typical surprise -15.1% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.20 vs $-0.17miss
- Tue, May 12$-0.21 vs $-0.14miss
- Wed, Mar 25$-0.16 vs $-0.18beat
- Thu, Nov 13$-0.19 vs $-0.17miss
- Mon, Aug 11$-0.22 vs $-0.18miss
- Thu, May 8$-0.25 vs $-0.21miss
Estimates and results for TELA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TELA officers and directors.
- Bought
- $4.2m
- Sold
- —
7 trades
0 trades
- Capper Joseph Hbought
- Capper Joseph Hbought
- Capper Joseph Hbought
- Capper Joseph Hbought
- Getz Heather Cbought
- Getz Heather Cbought
- Ew Healthcare Partners Fund 2, L.p.bought
93 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TELA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.